Racing Against Time

Dr. Aris P., a 58-year-old Professor of Biology from Athens, Greece.

Stage IV Non-Small Cell Lung Cancer (NSCLC) with a rare genetic mutation.

In early 2024, Dr. Aris faced a devastating reality. Standard chemotherapy and existing targeted therapies in Europe had failed. His medical team identified a newly FDA-approved targeted drug that showed remarkable efficacy for his specific mutation. However, the drug was estimated to take another 18 to 24 months to gain EMA approval and become available in Greek hospitals. For Aris, time was a luxury he didn’t have. His respiratory function was declining, and he was losing hope.

Aris’s daughter, also a researcher, discovered the Boao Lecheng International Medical Tourism Pilot Zone through a medical journal. She contacted LechengMedical for a pre-assessment. Within 72 hours, our team coordinated a remote MDT (Multi-Disciplinary Team) meeting between Aris’s Greek oncologist and the Chief of Oncology at a top-tier hospital in Lecheng.

We confirmed that the specific innovative drug was already available in Lecheng under the “First-Trial” policy. We managed the entire process: translating his extensive biopsy reports, securing the specialized medication, and arranging his 30-day visa-free entry. Aris arrived at Haikou International Airport and was whisked away by our VIP concierge directly to the medical zone.

Aris stayed in Lecheng for a 21-day treatment cycle. Under the supervision of experts experienced in “Licensed Special Medicines,” he received the new targeted therapy. By the second week, his cough had significantly subsided. A follow-up PET-CT scan showed a 30% reduction in tumor size. Today, Aris is back in Athens, continuing his maintenance therapy with the supply coordinated through our “Clinical Follow-up” program. He often says, “Lecheng didn’t just give me medicine; it gave me the years I thought I had lost.”